Symbiosis Secures $1.25M of Financing from Allied Irish Bank

Allied Irish Bank (GB) said it is providing $1.25 million of debt funding to Symbiosis, a Scottish contract development and manufacturing organization (CDMO). The funds will enable physical, operational and commercial development of the business, including enhanced manufacturing output, improved business process efficiency and a strengthened IT capability.

The financing will also support Symbiosis’s plan to hire 20 more staff by the end of 2020 and continue its trend of annual, double-digit revenue and profit increases.

The Allied Irish Bank (GB) finance package follows a recent period of expansion by Symbiosis, part-funded by Innovate UK grant funding.

Last year the firm completed the investment of $1.9 million in its Stirling headquarters, doubling its footprint and increasing its manufacturing capability.

Symbiosis provides niche, sterile manufacturing services to global biotechnology and pharmaceutical company clients that are developing novel drug therapies and vaccines for use in clinical trials or the commercial market.

Symbiosis’s facility at Stirling Innovation Park was purpose built in 2011 to manufacture deliberately small batches of clinical trial injectable drug products.

Since then, the company has grown significantly and has positioned itself to supply commercial pharmaceutical products and specialize in emerging medicinal technologies like Advanced Therapeutic Medicinal Products (ATMPs).

“Symbiosis has consistently exceeded its business goals and has strong potential for growth,” said Tina Crookston, relationship manager, Allied Irish Bank (GB). “We are working with many of our customers to support them through these difficult times, while identifying new opportunities in emerging sectors. Life sciences is a billion-pound sector in Scotland and homegrown startups like Symbiosis are a critical part of that success.”

Colin MacKay, chief executive officer, Symbiosis, said, “The funding from Allied Irish Bank (GB) is a significant statement of support and endorses our growth strategy. We will be using that investment to proactively fuel the strategic development of our capabilities to enable further successful growth in both local and international markets.”

He continued, “We want to increase our manufacturing output while maintaining the time-focused competitive strengths that our market has come to expect. It’s an exciting time for Symbiosis and we’re grateful for the support from Allied Irish Bank (GB) in recognizing our potential for growth and their willingness to join us in a mutually-beneficial relationship.”